For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies. However, the dynamic nature of cancer and limitations in tissue sampling have presented significant obstacles for clinicians. circulating tumor DNA (ctDNA), which is released into the bloodstream by tumor cells, offers a promising non-invasive alternative. It allows for real-time monitoring and comprehensive genetic profiling, providing new opportunities to track cancer progression and response to treatment without the need for repeated biopsies.
A study (DOI: 10.1093/pcmedi/pbae034) published on January 21, 2025, in Precision Clinical Medicine by researchers from the PRAEGNANT Network in Germany explores the clinical implications of ctDNA testing in advanced or metastatic…